TANDEM DIABETES CARE INC 8-K

What Happened
Tandem Diabetes Care, Inc. announced it completed a private offering of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 on February 27, 2026 (including full exercise of an initial purchasers’ option for an extra $35.0M). The Notes were issued under an indenture with U.S. Bank Trust Company, National Association as trustee. The Company also entered capped call transactions to reduce potential share dilution and offset certain cash conversion payments.

Key Details

• Offering size: $300.0 million aggregate principal (includes $35.0M option exercised); closing date February 27, 2026.
• Net proceeds: approximately $290.7 million; ~$15.3 million used to pay capped call costs; remaining proceeds for general corporate purposes (including possible acquisitions, working capital, operating expenses, capex).
• Note terms: 0.00% interest (no regular interest; principal does not accrete); maturity March 15, 2032; no sinking fund.
• Conversion: initial conversion rate 27.0362 shares per $1,000 principal (initial conversion price ≈ $36.99/share, ~37.5% premium to Feb 24, 2026 share price). Holders may convert freely on/after Dec 15, 2031; earlier conversions permitted only if specified price/other conditions are met. Upon conversion, the Company may pay cash, stock, or a combination.
• Redemption and repurchase: Company may not redeem before March 20, 2029; may redeem on/after that date if stock trades at ≥130% of conversion price for 20 of 30 trading days (redemption at 100% principal plus any accrued special interest). Holders may require repurchase at 100% principal upon certain fundamental changes.
• Capped calls: entered to reduce dilution/offset cash conversion obligations; initial cap price $47.0750 per share (~75.0% premium to Feb 24, 2026 price).
• Events of default and protections: customary covenants and default provisions in the indenture (payment defaults, failure to convert, bankruptcy events can accelerate repayment); certain reporting covenant breaches initially subject to limited remedy of special interest (tiered 0.25% then 0.50% per annum for specified periods).

Why It Matters
This financing increases Tandem’s liquidity by roughly $290.7M net, giving the company funding flexibility for operations, capital needs, and potential strategic moves without immediate cash interest expense. The convertible structure and capped calls seek to limit near-term dilution to common shareholders, but conversion terms, potential redemption conditions and the cap on conversion-related protections are important for equity holders to monitor. Investors should note timing windows for conversion and redemption, the zero-coupon nature of the notes, and the company’s stated intended uses of proceeds.